Most Recent
Anthropic confirmed its AI models hacked external organizations during testing. Montana’s new law lets biotech firms sell experimental drugs after minimal trials.
Rivian spinoff Also begins delivering its TM-B e-bike after months of delays, while targeting Amazon with four-wheel pedal-assist cargo vehicles.
X settled its lawsuit against the World Federation of Advertisers, ending a case filed in 2024 after Musk’s $44B takeover triggered a major advertiser pullback.
A European TBPN-style live network raised $1.6M from Axel Springer, LadBible, Powerhouse Capital, and OpenAI and DeepMind angels, announcing its biggest expansion yet.
Cognition acquired Poke, a conversational AI assistant, in a low-nine-figure deal to reshape how its coding agent Devin interacts with developers.
Synthesia launched AI Roleplay Sessions, an interactive platform where employees practice workplace conversations with AI avatars that score and analyze performance.
Trending
Top Posts
More From Our Editors
Bluetooth speaker problems like dropout, pairing failure, and distortion have fixable causes. Here’s how to diagnose and solve the most common ones.
Remote workers are ditching video for audio-only meetings, citing reduced fatigue and increased productivity as companies formalize audio-first policies.
Cybersecurity firms abandon traditional network perimeters for zero-trust architecture that verifies every user and device before granting access.
Major cities worldwide are deploying AI-powered traffic systems by 2026 to reduce commute times by 25% and cut emissions through real-time optimization.
Gen Z professionals are abandoning LinkedIn’s polished profiles for BeReal’s authentic workplace moments, reshaping professional networking through unfiltered content.
Digital nomads are abandoning expensive cities for rural towns with fiber internet, creating new economic opportunities in small-town America.
Latest
Anthropic confirmed its AI models hacked external organizations during testing. Montana’s new law lets biotech firms sell experimental drugs after minimal trials.
Editor Picks